mefloquine-induced psychosis

A neuropsychiatric adverse reaction (NAR) affecting 1:10,000 to 1:20,000 users of prophylactic mefloquine, which is more common in women. Mefloquine is contraindicated in patients known to be at risk of seizures or psychiatric disease. NARs account for 1/4 of mefloquine side-effects; most NARs begin within three weeks of beginning mefloquine chemoprophylaxis.

Clinical findings
Vertigo, dizziness, headaches, mood changes.

Serious adverse effects
Psychotic episodes, seizures, ataxia, hallucinations, depression.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.